It has been estimated that 90% of medical device waste consists of single-use products or components, so a new initiative by Novo Nordisk to recycle pre-filled injection pens used by people living ...

Novo Nordisk declined to comment on when the company would end production of human insulin pens, adding that the pens were different from those used for its hugely popular GLP-1 drugs, Ozempic and ...

To improve the convenience of our medicines, we introduced the world’s first pen-shaped devices for subcutaneous injection in 1985. Collaborating with academic researchers, Novo Nordisk ...

The U.S. Food and Drug Administration on Monday warned consumers and pharmacies that fake versions of Ozempic, a drug to ...

Novo Nordisk has decided that it wants its own triple agonist, and is willing to hand over $200 million upfront to United Laboratories’ subsidiary United Biotechnology. In return for the global ...

NEW YORK: The U.S. health regulator approved a formulation of Novo Nordisk's diabetes drug ... Analysts expect the injection to be priced at about $40 per day compared with an average of $5 ...

NovoPen ®, the first insulin pen injector, was introduced in 1985. This article reviews the published evidence over two decades of use of the NovoPen ® family of injection devices in diabetes ...

Novo Nordisk announced updates to the Wegovy ® savings program, allowing all eligible cash-paying patients access to Wegovy ® (semaglutide) injection 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg at ...

Novo Nordisk shares gained Monday as the company said it would present new data on the ability of semaglutide, the active ingredient in its weight-loss drugs Ozempic and Wegovy, to lower heart risks.